Although California voters last November approved a proposition that promises to push the state to the forefront of embryonic stem (ES) cell research, legislation introduced in the state senate last week may significantly constrain the way that the new California Institute for Regenerative Medicine (CIRM) conducts business.
Office of Strategic Communication